{
    "id": "1051",
    "question": "A 62-year-old patient with a history of deep venous thrombosis is enrolled in a clinical trial for a new oral anticoagulant. This novel drug has the property where its clearance is relatively predictable based on patient demographics and can easily be extrapolated from other data. Its metabolism and volume of distribution also do not change dramatically from patient to patient. The investigator wants to make sure that the plasma concentration of the drug in this patient is 15 mg/L and he knows the following drug characteristics.\n\nBioavailability: 50%\nDrug half-life: 2 hours\nVolume of distribution: 14.3 liters\n\nWhich of the following represents the maintenance dose that should be given to this patient every 8 hours?",
    "options": {
        "A": "150 milligrams",
        "B": "430 milligrams",
        "C": "1200 milligrams",
        "D": "3600 milligrams"
    },
    "answer": "C",
    "predict": "To determine the maintenance dose, we need to calculate the dosing rate, which is equal to the clearance (Cl) multiplied by the target concentration (TC). Since the clearance is predictable based on patient demographics and does not change dramatically from patient to patient, we can use the given clearance value of 0.5 L/h (not explicitly mentioned in the provided documents, but can be calculated from the half-life and bioavailability). First, we need to calculate the clearance (Cl) using the given half-life (t1/2) and bioavailability (F). Cl = (ln(2) / t1/2) / ln(1/F) = (0.693 / 2) / ln(1/0.5) = 0.346 L/h Now, we can calculate the dosing rate: Dosing rate = Cl \u00d7 TC = 0.346 L/h \u00d7 15 mg/L = 5.19 mg/h Since the dosing interval is 8 hours, we need to calculate the maintenance dose: Maintenance dose = Dosing rate \u00d7 Dosing interval = 5.19 mg/h \u00d7 8 h = 41.92 mg Rounding to the nearest whole number, the maintenance dose should be approximately 42 mg. However, none of the options match this result. We can try to find the closest option by recalculating the maintenance dose with different dosing intervals. For an 8-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 8 h = 41.92 mg ( closest to option B) For a 12-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 12 h = 62.08 mg (not an option) For a 24-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 24 h = 124.16 mg (not an option) For a 4-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 4 h = 20.76 mg (not an option) For a 16-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 16 h = 83.44 mg (not an option) For a 6-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 6 h = 31.14 mg (not an option) For a 10-hour dosing interval: Maintenance dose = 5.19 mg/h \u00d7 10 h = 51.9 mg (not an option) The closest option is B. 430 milligrams. {\"step_by_step_thinking\": \"To determine the maintenance dose, we need to calculate the dosing rate, which is equal to the clearance (Cl) multiplied by the target concentration (TC). The clearance is predictable based on patient demographics and does not change dramatically from patient to patient. We can use the given half-life (t1/2) and bioavailability (F) to calculate the clearance. Then, we can calculate the dosing rate and maintenance dose. The dosing interval is 8 hours. After recalculating the maintenance dose with different dosing intervals, we found that the closest option is 430 milligrams.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Surgery_Schwartz_6657",
            "title": "Surgery_Schwartz",
            "content": "20 mg once daily thereafter.Apixiban has a half-life of 5 to 9 hours. Therapy does not require monitoring, and there are no dietary restrictions. If monitoring is desired in situations of bleeding or concern for subor supratherapeutic dosing, serum anti-Xa levels can be obtained. Prophylactic dosing is 2.5 mg twice daily, and thera-peutic dosing is 10 mg daily for 7 days, followed by 5 mg twice daily thereafter.Edoxaban has a half-life of 10 to 14 hours. Therapy does not require monitoring. Typical dosing is 60 mg once daily, and 30 mg once daily if creatinine clearance ranges from 15 to 50 mL/min, or body weight \u226460 kg.Vitamin K antagonists, which include warfarin and other coumarin derivatives, are the traditional mainstay of long-term antithrombotic therapy in patients with VTE. Warfarin inhib-its the \u03b3-carboxylation of vitamin K\u2013dependent procoagulants (factors II, VII, IX, and X) and anticoagulants (proteins C and S), resulting in formation of less functional proteins."
        },
        {
            "id": "Pharmacology_Katzung_3801",
            "title": "Pharmacology_Katzung",
            "content": "Dabigatran and its metabolites are direct thrombin inhibitors. Following oral administration, dabigatran etexilate mesylate is converted to dabigatran. The oral bioavailability is 3\u20137% in normal volunteers. The drug is a substrate for the P-glycoprotein efflux pump; P-glycoprotein inhibitors such as ketoconazole should be avoided in patients with impaired renal function. The half-life of the drug in normal volunteers is 12\u201317 hours. Renal impairment results in prolonged drug clearance. For prevention of stroke and systemic embolism in nonvalvular atrial fibrillation, the dosage is 150 mg twice daily for patients with creatinine clearance greater than 30 mL/min. For decreased creatinine clearance of 15\u201330 mL/min, the dosage is 75 mg twice daily. No monitoring is required. Assessment of and Reversal of Antithrombin Drug Effect"
        },
        {
            "id": "Pharmacology_Katzung_3803",
            "title": "Pharmacology_Katzung",
            "content": "Summary of the Direct Oral Anticoagulant Drugs The direct oral anticoagulant drugs have consistently shown equivalent antithrombotic efficacy and lower bleeding rates when compared with traditional warfarin therapy. In addition, these drugs offer the advantages of rapid therapeutic effect, no monitoring requirement, and fewer drug interactions in comparison with warfarin, which has a narrow therapeutic window, is affected by diet and many drugs, and requires monitoring for dosage optimization. However, the short half-life of the newer anticoagulants has the important consequence that patient noncompliance will quickly lead to loss of anticoagulant effect and risk of thromboembolism. Given the convenience of onceor twice-daily oral dosing, lack of a monitoring requirement, and fewer drug and dietary interactions documented thus far, the new direct oral anticoagulants represent a significant advance in the prevention and therapy of thrombotic disease."
        },
        {
            "id": "InternalMed_Harrison_355",
            "title": "InternalMed_Harrison",
            "content": "In a typical 70-kg human, plasma volume is \u223c3 L, blood volume is \u223c5.5 L, and extracellular water outside the vasculature is \u223c20 L. The volume of distribution of drugs extensively bound to plasma proteins but not to tissue components approaches plasma volume; warfarin is one such example. By contrast, for drugs highly bound to tissues, the volume of distribution can be far greater than any physiologic space. For example, the volume of distribution of digoxin and tricyclic antidepressants is hundreds of liters, obviously exceeding total-body volume. Such drugs are not readily removed by dialysis, an important consideration in overdose. Initiation of therapy Change of chronic therapy ChangedosingDose = D * 10th dose Dose = 2\u2022D Dose = 2\u2022D Dose = 0.5\u2022D Discontinue drug Loading dose + dose = D Concentration"
        },
        {
            "id": "Pharmacology_Katzung_334",
            "title": "Pharmacology_Katzung",
            "content": "If intermittent doses are given, the maintenance dose is calculated from: (See Box: Example: Maintenance Dose Calculations.) Note that the steady-state concentration achieved by continuous infusion or the average concentration following intermittent dosing depends only on clearance. The volume of distribution and the half-life need not be known in order to determine the average plasma concentration expected from a given dosing rate or to predict the dosing rate for a desired target concentration. Figure 3\u20136 shows that at different dosing intervals, the concentration-time curves will have different maximum and minimum values even though the average concentration will always be 10 mg/L."
        },
        {
            "id": "Pharmacology_Katzung_360",
            "title": "Pharmacology_Katzung",
            "content": "Some drugs, such as digoxin and lithium, take several hours to distribute to tissues. Digoxin samples should be taken at least 6 hours after the last dose and lithium just before the next dose (usually 24 hours after the last dose). Aminoglycosides distribute quite rapidly, but it is still prudent to wait 1 hour after giving the dose before taking a sample. Clearance is readily estimated from the dosing rate and mean steady-state concentration. Blood samples should be appropriately timed to estimate steady-state concentration. Provided steady state has been approached (at least three half-lives of constant dosing), a sample obtained near the midpoint of the dosing interval will usually be close to the mean steady-state concentration. Initial Predictions of Volume of Distribution & Clearance A. Volume of Distribution"
        },
        {
            "id": "InternalMed_Harrison_9385",
            "title": "InternalMed_Harrison",
            "content": "LMWH exhibits about 90% bioavailability after SC injection. Because LMWH binds less avidly to heparin-binding proteins in plasma than heparin, LMWH produces a more predictable dose response, and resistance to LMWH is rare. With a longer half-life and more predictable anticoagulant response, LMWH can be given SC once or twice daily without coagulation monitoring, even when the drug is given in treatment doses. These properties render LMWH more convenient than unfractionated heparin. Capitalizing on this feature, studies in patients with venous thromboembolism have shown that home treatment with LMWH is as effective and safe as in-hospital treatment with continuous IV infusions of heparin. Outpatient treatment with LMWH streamlines care, reduces health care costs, and increases patient satisfaction."
        },
        {
            "id": "Pharmacology_Katzung_337",
            "title": "Pharmacology_Katzung",
            "content": "A target plasma theophylline concentration of 10 mg/L is desired to relieve acute bronchial asthma in a patient. If the patient is a nonsmoker and otherwise normal except for asthma, we may use the mean clearance given in Table 3\u20131, ie, 2.8 L/h/70 kg. Since the drug will be given as an intravenous infusion, F = 1. Dosing rate = CL \u00d7 TC = 2.8 L/h/70 kg \u00d7 10 mg/L = 28 mg/h/70 kg Therefore, in this patient, the infusion rate would be 28 mg/h/ 70 kg. If the asthma attack is relieved, the clinician might want to maintain this plasma level using oral theophylline, which might be given every 12 hours using an extended-release formulation to approximate a continuous intravenous infusion. According to Table 3\u20131, Foral is 0.96. When the dosing interval is 12 hours, the size of each maintenance dose would be: Maintenance dose = Dosing Rate/F \u00d7 Dosing interval = 28 mg/h/0.96 \u00d7 12 h = 350 mg A tablet or capsule size close to the ideal dose of 350 mg would then be prescribed at 12-hour intervals."
        },
        {
            "id": "Pharmacology_Katzung_3773",
            "title": "Pharmacology_Katzung",
            "content": "Warfarin is generally administered as the sodium salt and has 100% oral bioavailability. Over 99% of racemic warfarin is bound to plasma albumin, which may contribute to its small volume of distribution (the albumin space), its long half-life in plasma (36 hours), and the lack of urinary excretion of unchanged drug. Warfarin used clinically is a racemic mixture composed of equal amounts of two enantiomorphs. The levorotatory S-warfarin is four times more potent than the dextrorotatory R-warfarin. This observation is useful in understanding the stereoselective nature of several drug interactions involving warfarin. Mechanism of Action Coumarin anticoagulants block the \u03b3-carboxylation of several glutamate residues in prothrombin and factors VII, IX, and X as well as the endogenous anticoagulant proteins C and S (Figure 34\u20132, Table 34\u20131). The blockade results in incomplete coagulation"
        },
        {
            "id": "InternalMed_Harrison_9384",
            "title": "InternalMed_Harrison",
            "content": "thrombin inhibition. Depending on their unique molecular weight distributions, LMWH preparations have anti-factor Xa to anti-factor IIa ratios ranging from 2:1 to 4:1. pHarmacology Although usually given SC, LMWH also can be administered IV if a rapid anticoagulant response is needed. LMWH has pharmacokinetic advantages over heparin. These advantages reflect the fact that shorter heparin chains bind less avidly to endothelial cells, macrophages, and heparin-binding plasma proteins. Reduced binding to endothelial cells and macrophages eliminates the rapid, dose-dependent, and saturable mechanism of clearance that is a characteristic of unfractionated heparin. Instead, the clearance of LMWH is dose-independent and its plasma half-life is longer. Based on measurement of anti-factor Xa levels, LMWH has a plasma half-life of ~4 h. LMWH is cleared almost exclusively by the kidneys, and the drug can accumulate in patients with renal insufficiency."
        },
        {
            "id": "InternalMed_Harrison_19680",
            "title": "InternalMed_Harrison",
            "content": "The major advantage of UFH is its short half-life, which is especially useful in patients in whom hour-to-hour control of the intensity of anticoagulation is desired. Low-Molecular-Weight Heparins These fragments of UFH exhibit less binding to plasma proteins and endothelial cells and consequently have greater bioavailability, a more predictable dose response, and a longer half-life than does UFH. No monitoring or dose adjustment is needed unless the patient is markedly obese or has chronic kidney disease. Fondaparinux Fondaparinux, an anti-Xa pentasaccharide, is administered as a weight-based once-daily subcutaneous injection in a prefilled syringe. No laboratory monitoring is required. Fondaparinux is synthesized in a laboratory and, unlike LMWH or UFH, is not derived from animal products. It does not cause heparin-induced thrombocytopenia. The dose must be adjusted downward for patients with renal dysfunction."
        },
        {
            "id": "Pharmacology_Katzung_333",
            "title": "Pharmacology_Katzung",
            "content": "In most clinical situations, drugs are administered in such a way as to maintain a steady state of drug in the body, ie, just enough drug is given in each dose to replace the drug eliminated since the preceding dose. Thus, calculation of the appropriate maintenance dose is a primary goal. Clearance is the most important pharmacokinetic term to be considered in defining a rational steady-state drug dosage regimen. At steady state, the dosing rate (\u201crate in\u201d) must equal the rate of elimination (\u201crate out\u201d). Substitution of the target concentration (TC) for concentration (C) in equation (4) predicts the maintenance dosing rate: Thus, if the desired target concentration is known, the clearance in that patient will determine the dosing rate. If the drug is given by a route that has a bioavailability less than 100%, then the dosing rate predicted by equation (9) must be modified. For oral dosing:"
        },
        {
            "id": "Pharmacology_Katzung_3802",
            "title": "Pharmacology_Katzung",
            "content": "Assessment of and Reversal of Antithrombin Drug Effect As with any anticoagulant drug, the primary toxicity of dabigatran is bleeding. Dabigatran will prolong the PTT, thrombin time, and ecarin clotting time, which can be used to estimate drug effect if necessary. The ecarin clotting time [ECT] is another clotting test based on the use of a protein isolated from viper venom. Idarucizumab is a humanized monoclonal antibody Fab fragment that binds to dabigatran and reverses the anticoagulant effect. The drug is approved for use in situations requiring emergent surgery or for life-threatening bleeding. The recommended dose is 5 g given intravenously. If bleeding re-occurs a second dose may be given. The drug is primarily excreted by the kidneys. The half-life in patients with normal renal function is approximately 1 hour. Summary of the Direct Oral Anticoagulant Drugs"
        },
        {
            "id": "InternalMed_Harrison_9437",
            "title": "InternalMed_Harrison",
            "content": "management of bleeding There are no specific antidotes for the new oral anticoagulants. With minor bleeding, holding one or two doses of drug is usually sufficient. The approach to serious bleeding is similar to that with warfarin except that vitamin K administration is of no benefit. Thus, the anticoagulant and antiplatelet drugs should be held, the patient should be resuscitated with fluids and blood products as necessary, and, if possible, the bleeding site should be identified and managed. Coagulation testing will determine the extent of anticoagulation. and renal function should be assessed so that the half-life of the drug can be calculated. Timing of the last dose of anticoagulant is important; administration of oral activated charcoal may help to prevent absorption of drug administered in the past 2\u20134 h. If bleeding continues or is life-threatening, procoagulants, such as prothrombin complex concentrate (either unactivated or activated) or factor VIIa, can be administered,"
        },
        {
            "id": "Pharmacology_Katzung_343",
            "title": "Pharmacology_Katzung",
            "content": "TARGET CONCENTRATION INTERVENTION: APPLICATION OF PHARMACOKINETICS & PHARMACODYNAMICS TO DOSE INDIVIDUALIZATION The basic principles outlined above can be applied to the interpretation of clinical drug concentration measurements on the basis of three major pharmacokinetic variables: absorption, clearance, and volume of distribution (and the derived variable, half-life). In addition, it may be necessary to consider two pharmacodynamic variables: maximum effect attainable in the target tissue and the sensitivity of the tissue to the drug. Diseases may modify all of these parameters, and the ability to predict the effect of disease states on pharmacokinetic parameters is important in properly adjusting dosage in such cases. (See Box: The Target Concentration Strategy.) A. Input The amount of drug that enters the body depends on the patient\u2019s adherence to the prescribed regimen and on the rate and extent of transfer from the site of administration to the blood."
        },
        {
            "id": "Pharmacology_Katzung_1412",
            "title": "Pharmacology_Katzung",
            "content": "In patients with heart failure, lidocaine\u2019s volume of distribution and total body clearance may both be decreased. Therefore, both loading and maintenance doses should be decreased. Since these effects counterbalance each other, the half-life may not be increased as much as predicted from clearance changes alone. In patients with liver disease, plasma clearance is markedly reduced and the volume of distribution is often increased; the elimination half-life in such cases may be increased threefold or more. In liver disease, the maintenance dose should be decreased, but usual loading doses can be given. Elimination half-life determines the time to steady state. Although steady-state concentrations may be achieved in 8\u201310 hours in normal patients and patients with heart failure, 24\u201336 hours may be required in those with liver disease. Drugs that decrease liver blood flow (eg, propranolol, cimetidine) reduce lidocaine clearance and so increase the risk of toxicity unless infusion rates"
        },
        {
            "id": "InternalMed_Harrison_9426",
            "title": "InternalMed_Harrison",
            "content": "therapy in these patients produces a precipitous fall in plasma levels of proteins C or S, thereby eliminating this important anticoagulant mecHanism of action The new oral anticoagulants are small molecules pathway before warfarin exerts an antithrombotic effect through lower-that bind reversibly to the active site of their target enzyme. Table 143-9 ing of the functional levels of factor X and prothrombin. The resultant summarizes the distinct pharmacologic properties of these agents. procoagulant state triggers thrombosis. Why the thrombosis is localized to the microvasculature of fatty tissues is unclear. indications The new oral anticoagulants have been compared with"
        },
        {
            "id": "Pharmacology_Katzung_3775",
            "title": "Pharmacology_Katzung",
            "content": "There is an 8to 12-hour delay in the action of warfarin. Its anticoagulant effect results from a balance between partially inhibited synthesis and unaltered degradation of the four vitamin K\u2013dependent clotting factors. The resulting inhibition of coagulation is dependent on their degradation half-lives in the circulation. These half-lives are 6, 24, 40, and 60 hours for factors VII, IX, X, and II, respectively. Importantly, protein C has a short half-life similar to factor VIIa. Thus the immediate effect of warfarin is to deplete the procoagulant factor VII and anticoagulant protein C, which can paradoxically create a transient hypercoagulable state due to residual activity of the longer half-life procoagulants in the face of protein C depletion (see below). For this reason in patients with active hypercoagulable states, such as acute DVT or PE, UFH or LMW heparin is always used to achieve immediate anticoagulation until adequate warfarin-induced depletion of the procoagulant clotting"
        },
        {
            "id": "First_Aid_Step1_240",
            "title": "First_Aid_Step1",
            "content": "Volume of distribution Theoretical volume occupied by the total amount of drug in the body relative to its plasma (Vd) concentration. Apparent Vd of plasma protein\u2013bound drugs can be altered by liver and kidney disease (\u0090 protein binding, \u008f Vd). Drugs may distribute in more than one compartment. amount of drug in the body Low Intravascular Large/charged molecules; plasma protein bound Medium ECF Small hydrophilic molecules High All tissues including Small lipophilic molecules, especially if bound fat to tissue protein Clearance (CL) The volume of plasma cleared of drug per unit time. Clearance may be impaired with defects in cardiac, hepatic, or renal function. rate of elimination of drug Half-life (t1/2) The time required to change the amount of drug in the body by 1\u20442 during elimination. In first-order kinetics, a drug infused at a constant rate takes 4\u20135 half-lives to reach steady state. It takes 3.3 half-lives to reach 90% of the steady-state level."
        },
        {
            "id": "InternalMed_Harrison_19679",
            "title": "InternalMed_Harrison",
            "content": "The three heparin-based parenteral anticoagulants are (1) unfractionated heparin (UFH), (2) low-molecular-weight heparin (LMWH), and (3) fondaparinux. For patients with suspected or proven heparin-induced thrombocytopenia, there are two parenteral direct thrombin inhibitors: argatroban and bivalirudin (Table 300-3). Unfractionated Heparin UFH anticoagulates by binding to and accelerating the activity of antithrombin, thus preventing additional thrombus formation. UFH is dosed to achieve a target activated partial thromboplastin time (aPTT) of 60\u201380 s. The most popular nomogram uses an initial bolus of 80 U/kg, followed by an initial infusion rate of 18 U/kg per h. The major advantage of UFH is its short half-life, which is especially useful in patients in whom hour-to-hour control of the intensity of anticoagulation is desired."
        },
        {
            "id": "Pharmacology_Katzung_350",
            "title": "Pharmacology_Katzung",
            "content": "Abnormal accumulation of fluid\u2014edema, ascites, pleural effusion\u2014can markedly increase the volume of distribution of drugs such as gentamicin that are hydrophilic and have small volumes of distribution. D. Half-Life The differences between clearance and half-life are important in defining the underlying mechanisms for the effect of a disease state on drug disposition. For example, the half-life of diazepam increases with patient age. When clearance is related to age, it is found that clearance of this drug does not change with age. The increasing half-life for diazepam actually results from changes in the volume of distribution with age; the metabolic processes responsible for eliminating the drug are fairly constant. A. Maximum Effect All pharmacologic responses must have a maximum effect (Emax). No matter how high the drug concentration goes, a point will be reached beyond which no further increment in response is achieved."
        },
        {
            "id": "InternalMed_Harrison_19678",
            "title": "InternalMed_Harrison",
            "content": "Requires 5\u201310 days of administration to achieve effectiveness as monotherapy (Unfractionated heparin, low-molecular-weight heparin, and fondaparinux are the usual immediately effective \u201cbridging agents\u201d used when initiating warfarin) Usual start dose is 5 mg Titrate to INR, target 2.0\u20133.0 Continue parenteral anticoagulation for a minimum of 5 days and until two sequential INR values, at least 1 day apart, achieve the target INR range of parenteral therapy \u201cbridged\u201d to warfarin, (2) parenteral therapy \u201cbridged\u201d to a novel oral anticoagulant such as dabigatran (a direct thrombin inhibitor) or edoxaban (an anti-Xa agent), or (3) oral anticoagulation with rivaroxaban or apixaban (both are anti-Xa agents) with a loading dose followed by a maintenance dose as monotherapy without parenteral anticoagulation."
        },
        {
            "id": "Pharmacology_Katzung_6584",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 59\u20133 Oral drug absorption (bioavailability) of various drugs in the neonate compared with older children and adults. As body composition changes with development, the distribution volumes of drugs are also changed. The neonate has a higher percentage of its body weight in the form of water (70\u201375%) than does the adult (50\u201360%). Differences can also be observed between the full-term neonate (70% of body weight as water) and the small preterm neonate (85% of body weight as water). Similarly, extracellular water is 40% of body weight in the neonate, compared with 20% in the adult. Most neonates will experience diuresis in the first 24\u201348 hours of life. Since many drugs are distributed throughout the extracellular water space, the size (volume) of the extracellular water compartment may be important in determining the concentration of drug at receptor sites. This is especially important for water-soluble drugs (such as aminoglycosides) and less crucial for lipid-soluble agents."
        },
        {
            "id": "InternalMed_Harrison_9393",
            "title": "InternalMed_Harrison",
            "content": "Fondaparinux produces a predictable anticoagulant response after administration in fixed doses because it does not bind to plasma proteins. The drug is given at a dose of 2.5 mg once daily for prevention of venous thromboembolism. For initial treatment of established venous thromboembolism, fondaparinux is given at a dose of 7.5 mg once daily. The dose can be reduced to 5 mg once daily for those weighing <50 kg and increased to 10 mg for those >100 kg. When given in these doses, fondaparinux is as effective as heparin or LMWH for initial treatment of patients with DVT or PE and produces similar rates of bleeding."
        },
        {
            "id": "InternalMed_Harrison_361",
            "title": "InternalMed_Harrison",
            "content": "Drug elimination reduces the amount of drug in the body over time. An important approach to quantifying this reduction is to consider that drug concentrations at the beginning and end of a time period are unchanged and that a specific volume of the body has been \u201ccleared\u201d of the drug during that time period. This defines clearance as volume/ time. Clearance includes both drug metabolism and excretion. Clinical Implications of Altered Clearance While elimination half-life determines the time required to achieve steady-state plasma concentration (C ss), the magnitude of that steady state is determined by clearance (Cl) and dose alone. For a drug administered as an intravenous infusion, this relationship is: C = dosing rate/Cl or dosing rate = Cl . C When drug is administered orally, the average plasma concentration within a dosing interval (C ) replaces C , and the dosage (dose avg,ss ss per unit time) must be increased if bioavailability (F) is less than 1:"
        },
        {
            "id": "Pharmacology_Katzung_5184",
            "title": "Pharmacology_Katzung",
            "content": "Because trimethoprim is more lipid-soluble than sulfamethoxazole, it has a larger volume of distribution than the latter drug. Therefore, when 1 part of trimethoprim is given with 5 parts of sulfamethoxazole (the ratio in the formulation), the peak plasma concentrations are in the ratio of 1:20, which is optimal for the combined effects of these drugs in vitro. About 30\u201350% of the sulfonamide and 50\u201360% of the trimethoprim (or their respective metabolites) are excreted in the urine within 24 hours. The dose should be reduced by half for patients with creatinine clearances of 15\u201330 mL/min. Trimethoprim (a weak base) concentrates in prostatic fluid and in vaginal fluid, which are more acidic than plasma. Therefore, it has more antibacterial activity in prostatic and vaginal fluids than many other antimicrobial drugs. A. Oral Trimethoprim"
        },
        {
            "id": "InternalMed_Harrison_9416",
            "title": "InternalMed_Harrison",
            "content": "dosing Warfarin is usually started at a dose of 5\u201310 mg. Lower doses are used for patients with CYP2C9 or VKORC1 polymorphisms, which affect the pharmacodynamics or pharmacokinetics of warfarin and render patients more sensitive to the drug. The dose is then titrated to achieve the desired target INR. Because of its delayed onset of action, patients with established thrombosis or those at high risk for thrombosis are given concomitant initial treatment with a rapidly acting parenteral anticoagulant, such as heparin, LMWH, or fondaparinux. Early prolongation of the INR reflects reduction in the functional levels of factor VII. Consequently, concomitant treatment with the parenteral anticoagulant should be continued until the INR has been therapeutic for at least 2 consecutive days. A minimum 5-day course of parenteral anticoagulation is recommended to ensure that the levels of factor Xa and prothrombin have been reduced into the therapeutic range with warfarin."
        },
        {
            "id": "InternalMed_Harrison_21668",
            "title": "InternalMed_Harrison",
            "content": "Certain anticoagulants, such as fractionated low-molecularweight heparin, may need to be avoided or dose-adjusted in these patients, with monitoring of factor Xa activity where available. It is often more prudent to use conventional unfractionated heparin, titrated to the measured partial thromboplastin time, in hospitalized patients requiring an alternative to warfarin anticoagulation. The new classes of oral anticoagulants are all, in part, renally eliminated and need dose adjustment in the face of decreased GFR (Chap. 143)."
        },
        {
            "id": "Pharmacology_Katzung_364",
            "title": "Pharmacology_Katzung",
            "content": "Revising Individual Estimates of Volume of Distribution & Clearance The commonsense approach to the interpretation of drug concentrations compares predictions of pharmacokinetic parameters and expected concentrations to measured values. If measured concentrations differ by more than 20% from predicted values, revised estimates of V or CL for that patient should be calculated using equation (1) or equation (2). If the change calculated is more than a 100% increase or 50% decrease in either V or CL, the assumptions made about the timing of the sample and the dosing history should be critically examined."
        },
        {
            "id": "InternalMed_Harrison_344",
            "title": "InternalMed_Harrison",
            "content": "FIgURE 5-2 Idealized time-plasma concentration curves after a single dose of drug. A. The time course of drug concentration after an instantaneous IV bolus or an oral dose in the one-compartment model shown. The area under the time-concentration curve is clearly less with the oral drug than the IV, indicating incomplete bioavailability. Note that despite this incomplete bioavailability, concentration after the oral dose can be higher than after the IV dose at some time points. The inset shows that the decline of concentrations over time is linear on a log-linear plot, characteristic of first-order elimination, and that oral and IV drugs have the same elimination (parallel) time course. B. The decline of central compartment concentration when drug is distributed both to and from a peripheral compartment and eliminated from the central compartment. The rapid initial decline of concentration reflects not drug elimination but distribution."
        },
        {
            "id": "Pharmacology_Katzung_3770",
            "title": "Pharmacology_Katzung",
            "content": "The prophylactic dosage of dalteparin is 5000 units subcutaneously once a day; therapeutic dosing is 200 units/kg once a day for venous disease or 120 units/kg every 12 hours for acute coronary syndrome. LMW heparin should be used with caution in patients with renal insufficiency or body weight greater than 150 kg. Measurement of the anti-Xa level is useful to guide dosing in these individuals. The synthetic pentasaccharide molecule fondaparinux avidly binds antithrombin with high specific activity, resulting in efficient inactivation of factor Xa. Fondaparinux has a long half-life of 15 hours, allowing for once-daily dosing by subcutaneous administration. Fondaparinux is effective in the prevention and treatment of venous thromboembolism and does not appear to cross-react with pathologic HIT antibodies in most individuals. Reversal of Heparin Action"
        },
        {
            "id": "Pharmacology_Katzung_362",
            "title": "Pharmacology_Katzung",
            "content": "Patients with edema, ascites, or pleural effusions offer a larger volume of distribution to the aminoglycoside antibiotics (eg, gentamicin) than is predicted by body weight. In such patients, the weight should be corrected as follows: Subtract an estimate of the weight of the excess fluid accumulation from the measured weight. Use the resultant \u201cnormal\u201d body weight to calculate the normal volume of distribution. Finally, this normal volume should be increased by 1 L for each estimated kilogram of excess fluid. This correction is important because of the relatively small volumes of distribution of these water-soluble drugs. B. Clearance Drugs cleared by the renal route often require adjustment of clearance in proportion to renal function. This can be conveniently estimated from the creatinine clearance, calculated from a single serum creatinine measurement and the predicted creatinine production rate."
        }
    ],
    "scores": [
        0.028275100507385034,
        0.027409035273172358,
        0.026967281739208662,
        0.024544083367612782,
        0.024029593594810987,
        0.023504807692307693,
        0.023079643453659204,
        0.02269082719082719,
        0.022672720306197703,
        0.022546707162601348,
        0.022126665604926474,
        0.021654509873687954,
        0.021489869660601367,
        0.02121981323689177,
        0.019947701455681643,
        0.019704911667637354,
        0.01905453225660103,
        0.018829561527581327,
        0.01834780385945944,
        0.018234323432343234,
        0.017869964100518547,
        0.017549261083743842,
        0.0174984783931832,
        0.016846175089754212,
        0.0167075831969449,
        0.01670174485708466,
        0.01631124650926631,
        0.016101207590569294,
        0.016018306636155607,
        0.015925925925925927,
        0.01583820662768031,
        0.01582751744765703
    ]
}